In Asia Pacific, China is experiencing rapid growth in the oxycodone drugs market, driven by an increasing number of patients with cancer and other chronic pain conditions. Japan and South Korea also show significant market potential due to the growing awareness about pain management and the improving healthcare infrastructure in these countries.
In Europe, the United Kingdom, Germany, and France are key markets for oxycodone drugs. These countries have well-established healthcare systems and high prescription rates for opioids. The market growth in Europe is also supported by the rising geriatric population and the increasing prevalence of chronic pain conditions.